kidney disease glp 1 Use of Anti-Diabetic Agents in Non-Diabetic Disease: From Bench to Bedside Glucagon-like Peptide Receptor Agonists and

Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance

Maintaining Results After Long-Term Semaglutide Use Patients who have completed extended semaglutide therapy face a critical decision: continuing indefinitely, transitioning to a lower maintenance dose, or stopping with structured lifestyle support to prevent rebound weight gain

Clinical trials show that patients using these medications experience slower gastric transit times by 2040% compared to baseline

List of Key Companies Novo Nordisk A/S Valbiotis RESVERLOGIX Caelus Health Scimar Boston Pharmaceuticals APHAIA PHARMA AG AstraZeneca Bristol-Myers Squibb Company Pfizer Inc

7 Despite the growing evidence of the CV benefits of GLP-1 RAs and dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists/GLP-1 RAs in T2D patients and their inclusion in guidelines, lack of awareness of the CV benefits of GLP-1 RAs and dual GIP/GLP-1 RAs, clinical inertia, resistance to injectable medications and concerns about treatment costs have hindered the widespread adoption of GLP-1 RAs

Atypical presentation of a preexisting pancreatic pseudocyst with glucagon-like peptide-1 agonist as a possible trigger for exacerbation: a case report